CVRx, Inc. (CVRX)
Nasdaq · Healthcare · Medical Devices
$1.56+0.65%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $41.6M
- 52-week range
- $1.50 – $11.30
- 52-week change
- −82.25%
- EPS (trailing)
- −$1.97
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $56.7M (+10.45%)
- Net income
- −$53.3M
- Operating margin
- −90.5%
- Diluted EPS
- −$2.04
- Free cash flow
- −$40.8M
From the company’s annual report on SEC EDGAR.
About CVRx, Inc.
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Headquarters: Minneapolis, United States · 223 employees · barostim.com